Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Trust, Surrey and London, UK.
Liver Int. 2019 May;39 Suppl 1:32-42. doi: 10.1111/liv.14085. Epub 2019 Mar 24.
The complexity of cholangiocarcinoma (CCA) cellularity and the molecular perturbation mechanisms that underlie the diversity of growth patterns of this malignancy remain a clinical concern. Tumours of the biliary system display significant intrinsic chemoresistance, caused by significant stromal involvement and genome-wide tumour heterogeneity, hampering disease remission and palliation as well as promoting the metastatic behaviour. It is crucial to advance our present understanding of the risk and molecular pathogenesis of CCA. This will facilitate the delineation of patient subsets based on molecular perturbations and adjust for precision therapies.
胆管癌（CCA）的细胞复杂性以及导致这种恶性肿瘤生长模式多样性的分子扰动机制仍然是临床关注的问题。胆道系统的肿瘤由于存在明显的基质浸润和全肿瘤异质性，表现出显著的内在化疗耐药性，这阻碍了疾病的缓解和姑息治疗，并促进了转移行为。推进我们对 CCA 的风险和分子发病机制的现有认识至关重要。这将有助于根据分子扰动来描绘患者亚群，并调整精准治疗。
